Medios AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/30/2026)
| Balance Sheet | Total Assets | 903,041,000.00 | ROE | 56.94 % |
| Balance Sheet | Total Equity | 514,219,000.00 | ROA | 1.70 % |
| Cashflow | Capital Expenditures | -6,065,000.00 | P/FCF | 6.96 |
| Cashflow | Free Cash Flow | 36,937,000.00 | – | – |
| Cashflow | Operating Cash Flow | 43,002,000.00 | P/CF | 5.98 |
| Income | Earnings per Share (diluted) | 0.64 | Div. Yield | – |
| Income | Net Income | 15,365,000.00 | P/E | 16.03 |
| Income | Shares Outstanding | 25,047,000.00 | P/B | 0.50 |
| Income | Total Revenue | 2,078,650,000.00 | P/S | 0.12 |
Ratios calculated on: 10/14/2026
Company Description
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. The company offers infusions for patients with rare or chronic diseases, such as cancer, HIV, and hepatitis. It also manufactures drugs for patients on behalf of pharmacies. The company was founded in 2016 and is headquartered in Berlin, Germany. Medios AG is a subsidiary of mediosmanagement GmbH.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.medios.ag
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more